Arbutus BiopharmavsAmgen

ABUS and AMGN stock compared: price, dividend, valuation and results, from SEC filings.

ABUS

Arbutus Biopharma Corporation

$4.02

Value $799M

-1.23%
ABUS's page

AMGN

Amgen Inc.

$435.64

Value $235B

-0.72%
AMGN's page

Arbutus Biopharma (ABUS) has a market value of $799M and Amgen (AMGN) $235B. Over the last year, with dividends, ABUS moved -5.9% and AMGN +31.5%. The P/E is 3.6 for ABUS and 25.0 for AMGN. Dividend yield: ABUS none, AMGN 2.31%.

At a glance

The main figures of both. A bar only shows which number is larger, not which is better.

  • Market value

    ABUS$799M

    AMGN$235B

    AMGN is 294 times ABUS

  • Revenue, 12 months

    ABUS$181M

    AMGN$38.9B

    AMGN is 214 times ABUS

  • Net income, 12 months

    ABUS$220M

    AMGN$9.4B

    AMGN is 43 times ABUS

  • Operating margin

    ABUS81.1%

    AMGN32.4%

    48.7 points apart

  • ROIC

    ABUS76.6%

    AMGN16.2%

    60.4 points apart

  • P/E

    ABUS3.6

    AMGN25.0

    AMGN is 6.9 times ABUS

  • Dividend yield

    ABUS0.0%

    AMGN2.3%

    2.3 points apart

  • 5-year return

    ABUS+21.8%

    AMGN+146.3%

    124.5 points apart

A fainter bar means a negative number. The 5-year return includes dividends.

The price over time

Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.

ABUS+21.8%

AMGN+146.4%

10020020222023202420252026
Returns by period
PeriodABUSWith dividendsAMGNWith dividends
1 year since November 19, 2025-5.9%Price -5.9%+31.5%Price +27.2%
3 years since November 20, 2023+118.5%+29.8% a yearPrice +118.5%+79.2%+21.5% a yearPrice +64.2%
5 years since November 19, 2021+21.8%+4.0% a yearPrice +21.8%+146.3%+19.8% a yearPrice +111.4%
10 years since November 21, 2016+48.9%+4.1% a yearPrice +48.9%+302.7%+14.9% a yearPrice +199.3%

Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.

Every figure

As on each company's page. A description, not a recommendation: no one figure says which is better.

ABUSArbutus BiopharmaAMGNAmgen

Valuation

ABUSAMGN
Valuation
Price$4.02$435.64
Market value$799M$235B
Enterprise value (EV)$461M$276B
P/E3.625.0
P/E, 5-year median–23.0
P/B9.316.4
EV/EBIT3.121.9
Free cash flow yield27.7%4.1%

Results and growth

ABUSAMGN
Results and growth
Revenue, 12 months$181M$38.9B
Net income, 12 months$220M$9.4B
Free cash flow, 12 months$221M$9.6B
Earnings per share, 12 months$1.13$17.25
Revenue growth, year on year128.2%10.0%
Revenue growth a year, past+15.3%over 5 years+7.6%over 5 years
EPS growth a year, past–+2.9%over 5 years

Margins and returns on capital

ABUSAMGN
Margins and returns on capital
Gross margin–70.9%
Operating margin81.1%32.4%
Net margin121.2%24.1%
ROIC76.6%16.2%
ROE144.9%87.8%

Balance sheet

ABUSAMGN
Balance sheet
Cash$337M$13.2B
Total debt$328.0K$54.0B
Net debt / EBITDA-2.32.3
Interest cover2,299.4×4.8×

Dividends and buybacks

ABUSAMGN
Dividends and buybacks
Dividend yield–2.3%
Dividend per share, 12 months–$10.08
Dividend growth a year, past–+8.1%over 5 years
Buyback yield––
Shareholder yield–2.3%

Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.

Questions: ABUS or AMGN

Didn't find what you were looking for?

Ask us
Which is bigger, Arbutus Biopharma or Amgen?

By market value, Amgen ($235B) is about 294.0 times Arbutus Biopharma ($799M), at today's prices.

How did ABUS and AMGN stock do over the last 10 years?

Since November 21, 2016, ABUS's price moved +48.9% and AMGN's +199.3%. With dividends: ABUS +48.9% (+4.1% a year), AMGN +302.7% (+14.9% a year). Past returns do not predict future ones.

Which pays the higher dividend, ABUS or AMGN?

The dividend yield at today's price is none for Arbutus Biopharma and 2.31% for Amgen. Over the last twelve months they paid – and $10.08 per share.

What is the P/E of ABUS and AMGN?

At today's price, the P/E is 3.6 for ABUS and 25.0 for AMGN. It is the share price over the last twelve months' earnings per share.

Which has the higher profit margins, Arbutus Biopharma or Amgen?

Over the last twelve months, the net margin was 121.2% for Arbutus Biopharma and 24.1% for Amgen, and the operating margin 81.1% and 32.4%. Revenue was $181M and $38.9B.

Which is the better investment, Arbutus Biopharma or Amgen?

The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.

Other comparisons

With each of the two, and with the largest in its sector.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

Descriptive data from SEC filings and market prices.